Table of Content

1 INTRODUCTION (Page No. - 27)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
                    FIGURE 1 MARKET SEGMENTATION
           1.3.2 REGIONS COVERED
                    FIGURE 2 REGIONAL SEGMENTATION
           1.3.3 YEARS CONSIDERED
           1.3.4 CURRENCY CONSIDERED
    1.4 STAKEHOLDERS 
    1.5 RECESSION IMPACT 
2 RESEARCH METHODOLOGY (Page No. - 31)
    2.1 RESEARCH DATA 
          FIGURE 3 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 4 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET ESTIMATION METHODOLOGY 
          FIGURE 5 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
          FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
           2.2.1 INSIGHTS FROM PRIMARY EXPERTS
                    FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
    2.3 MARKET GROWTH RATE PROJECTIONS 
          FIGURE 8 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET (SUPPLY-SIDE): CAGR PROJECTIONS
          FIGURE 9 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    2.4 DATA TRIANGULATION AND MARKET BREAKDOWN 
          FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.5 RESEARCH ASSUMPTIONS 
    2.6 RISK ASSESSMENT ANALYSIS 
          TABLE 1 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: RISK IMPACT ANALYSIS
    2.7 RECESSION IMPACT ANALYSIS 
          TABLE 2 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
          TABLE 3 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 4 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)

3 EXECUTIVE SUMMARY (Page No. - 42)
    FIGURE 11 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2029 VS. 2032 (USD MILLION)
    FIGURE 12 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY PRODUCT & SERVICE, 2029 VS. 2032 (USD MILLION)
    FIGURE 13 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2029 VS. 2032 (USD MILLION)
    FIGURE 14 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY APPLICATION, 2029 VS. 2032 (USD MILLION)
    FIGURE 15 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2029 VS. 2032 (USD MILLION)
    FIGURE 16 GEOGRAPHICAL SNAPSHOT OF EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET
4 PREMIUM INSIGHTS (Page No. - 47)
    4.1 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET OVERVIEW 
          FIGURE 17 EMERGING POTENTIAL OF EXOSOME-BASED LIQUID BIOPSY TO DRIVE MARKET
    4.2 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE AND COUNTRY (2029) 
          FIGURE 18 EXOSOME THERAPEUTICS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2029
    4.3 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2029 VS. 2032 (USD MILLION) 
          FIGURE 19 EXOSOME DIAGNOSTICS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 49)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 20 EXOSOME DIAGNOSTICS AND THERAPEUTIC MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          TABLE 5 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Emerging potential of exosome-based liquid biopsy
                    5.2.1.2 Increasing initiatives for product commercialization
                    5.2.1.3 Growing outsourcing of exosome-based manufacturing activities
           5.2.2 RESTRAINTS
                    5.2.2.1 Technical complexities associated with exosome isolation
                    5.2.2.2 Stringent regulatory requirements
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growing adoption of exosome biomarkers for personalized medicine
           5.2.4 CHALLENGES
                    5.2.4.1 Inadequate protocols for exosome development & production
    5.3 SUPPLY CHAIN ANALYSIS 
          FIGURE 21 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS
    5.4 VALUE CHAIN ANALYSIS 
          FIGURE 22 VALUE CHAIN ANALYSIS: MANUFACTURING PROCESSES AND REGULATORY INVESTMENTS ADD MAXIMUM VALUE
    5.5 PATENT ANALYSIS 
           5.5.1 PATENT ANALYSIS: EXOSOME DIAGNOSTICS
                    FIGURE 23 PATENT APPLICATIONS FOR EXOSOME DIAGNOSTICS, JANUARY 2013–OCTOBER 2023
                    FIGURE 24 PATENT APPLICATIONS FOR EXOSOME DIAGNOSTICS, BY JURISDICTION
           5.5.2 PATENT ANALYSIS: EXOSOME THERAPEUTICS
                    FIGURE 25 PATENT APPLICATIONS FOR EXOSOME THERAPEUTICS, JANUARY 2013–OCTOBER 2023
                    FIGURE 26 PATENT APPLICATIONS FOR EXOSOME THERAPEUTICS, BY JURISDICTION
    5.6 REGULATORY LANDSCAPE 
           5.6.1 REGULATORY SCENARIO
                    5.6.1.1 North America
                               5.6.1.1.1 US
                               5.6.1.1.2 Canada
                    5.6.1.2 Europe
                               5.6.1.2.1 Germany
                               5.6.1.2.2 Spain
                    5.6.1.3 Asia Pacific
                               5.6.1.3.1 China
                               5.6.1.3.2 Japan
                               5.6.1.3.3 South Korea
           5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 6 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.7 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 7 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.7.1 THREAT OF NEW ENTRANTS
           5.7.2 THREAT OF SUBSTITUTES
           5.7.3 BARGAINING POWER OF SUPPLIERS
           5.7.4 BARGAINING POWER OF BUYERS
           5.7.5 INTENSITY OF COMPETITIVE RIVALRY
    5.8 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
                    FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EXOSOME DIAGNOSTICS & THERAPEUTICS
           5.8.2 BUYING CRITERIA FOR END USERS
                    FIGURE 28 KEY BUYING CRITERIA FOR END USERS
    5.9 INVESTMENT AND FUNDING SCENARIO 
          TABLE 8 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: INVESTMENT & FUNDING SCENARIO
    5.10 EXOSOME THERAPEUTICS: DEVELOPMENT & MANUFACTURING PROCESS 
           5.10.1 EXOSOME ISOLATION
                     TABLE 9 EXOSOME ISOLATION TECHNIQUES
           5.10.2 EXOSOME CHARACTERIZATION AND QC
           5.10.3 EXOSOME PRODUCTION
    5.11 PIPELINE ANALYSIS 
           FIGURE 29 EXOSOME PIPELINE, BY INTERVENTION TYPE
           FIGURE 30 EXOSOME PIPELINE, BY PHASE
           5.11.1 PIPELINE ANALYSIS: EXOSOME THERAPEUTICS
                     FIGURE 31 EXOSOME THERAPEUTICS PIPELINE, BY PHASE
                     FIGURE 32 EXOSOME THERAPEUTICS PIPELINE, BY REGION
           5.11.2 PIPELINE ANALYSIS: EXOSOME DIAGNOSTICS
                     FIGURE 33 EXOSOME DIAGNOSTIC TESTS PIPELINE, BY APPLICATION
                     FIGURE 34 EXOSOME DIAGNOSTIC TESTS PIPELINE, BY COUNTRY
                     TABLE 10 PIPELINE PRODUCTS FOR EXOSOME DIAGNOSTICS
                     TABLE 11 PIPELINE PRODUCTS FOR EXOSOME THERAPEUTICS
    5.12 PRICING ANALYSIS 
           5.12.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
                     TABLE 12 AVERAGE SELLING PRICE OF EXOSOME DIAGNOSTIC PRODUCTS, BY KEY PLAYER
           5.12.2 AVERAGE SELLING PRICE TREND, BY REGION
    5.13 ECOSYSTEM ANALYSIS 
           FIGURE 35 EXOSOME DIAGNOSTICS AND THERAPEUTICS: ECOSYSTEM MAP
    5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
           FIGURE 36 REVENUE SHIFT AND NEW POCKETS
    5.15 KEY CONFERENCES & EVENTS 
           TABLE 13 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2024–2025)
    5.16 TECHNOLOGY ANALYSIS 
           5.16.1 KEY TECHNOLOGIES
                     TABLE 14 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: KEY TECHNOLOGIES
           5.16.2 COMPLIMENTARY TECHNOLOGIES
           5.16.3 ADJACENT TECHNOLOGIES
6 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE (Page No. - 90)
    6.1 INTRODUCTION 
          TABLE 15 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 16 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
    6.2 EXOSOME DIAGNOSTICS 
           6.2.1 GROWING FOCUS ON EARLY DISEASE DETECTION & DIAGNOSIS TO PROPEL MARKET
                    TABLE 17 EXOSOME DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 18 EXOSOME DIAGNOSTICS MARKET, BY REGION, 2030–2032 (USD MILLION)
                    TABLE 19 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 20 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 21 EUROPE: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 22 EUROPE: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 23 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 24 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
    6.3 EXOSOME THERAPEUTICS 
           6.3.1 INCREASING NUMBER OF CLINICAL TRIALS TO SUPPORT MARKET GROWTH
                    TABLE 25 EXOSOME THERAPEUTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 26 EXOSOME THERAPEUTICS MARKET, BY REGION, 2030–2032 (USD MILLION)
                    TABLE 27 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 28 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 29 EUROPE: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 30 EUROPE: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 31 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 32 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
7 EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 98)
    7.1 INTRODUCTION 
          TABLE 33 EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
          TABLE 34 EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2030–2032 (USD MILLION)
    7.2 KITS & REAGENTS 
           7.2.1 GROWING DEMAND FOR NON-INVASIVE DIAGNOSTIC KITS TO DRIVE MARKET
                    TABLE 35 EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 36 EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY REGION, 2030–2032 (USD MILLION)
                    TABLE 37 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 38 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 39 EUROPE: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 40 EUROPE: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 41 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 42 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030–2032 (USD MILLION)
    7.3 INSTRUMENTS & SERVICES 
           7.3.1 RISING FOCUS ON OUTSOURCING EXOSOME PREPARATION ACTIVITIES TO SUPPORT MARKET GROWTH
                    TABLE 43 EXOSOME DIAGNOSTICS MARKET FOR INSTRUMENTS & SERVICES, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 44 EXOSOME DIAGNOSTICS MARKET FOR INSTRUMENTS & SERVICES, BY REGION, 2030–2032 (USD MILLION)
8 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE (Page No. - 104)
    8.1 INTRODUCTION 
          TABLE 45 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
          TABLE 46 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
    8.2 STEM CELLS 
           8.2.1 GROWING UPTAKE OF MSC-DERIVED EXOSOMES IN CELLULAR PROCESSES TO DRIVE MARKET
                    TABLE 47 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 48 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY REGION, 2030–2032 (USD MILLION)
                    TABLE 49 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 50 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 51 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 52 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 53 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 54 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030–2032 (USD MILLION)
    8.3 BLOOD & BLOOD PLASMA 
           8.3.1 ABILITY TO ENHANCE TREATMENT RESPONSE AND DISEASE DIAGNOSIS TO BOOST DEMAND
                    TABLE 55 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 56 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY REGION, 2030–2032 (USD MILLION)
                    TABLE 57 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 58 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 59 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 60 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 61 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 62 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030–2032 (USD MILLION)
    8.4 URINE 
           8.4.1 RAPID COMMERCIALIZATION OF URINE SAMPLE-BASED DIAGNOSTIC TESTS TO DRIVE MARKET
                    TABLE 63 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 64 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY REGION, 2030–2032 (USD MILLION)
                    TABLE 65 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 66 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 67 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 68 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 69 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 70 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030–2032 (USD MILLION)
    8.5 OTHER SAMPLES 
          TABLE 71 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY REGION, 2022–2029 (USD MILLION)
          TABLE 72 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY REGION, 2030–2032 (USD MILLION)
          TABLE 73 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 74 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030–2032 (USD MILLION)
          TABLE 75 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 76 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030–2032 (USD MILLION)
          TABLE 77 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 78 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030–2032 (USD MILLION)
9 EXOSOME THERAPEUTICS MARKET, BY APPLICATION (Page No. - 118)
    9.1 INTRODUCTION 
          TABLE 79 EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
          TABLE 80 EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
    9.2 CANCER 
           9.2.1 GROWING FOCUS ON ONCOLOGY THERAPEUTICS TO PROPEL MARKET
                    TABLE 81 EXOSOME THERAPEUTICS MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 82 EXOSOME THERAPEUTICS MARKET FOR CANCER, BY REGION, 2030–2032 (USD MILLION)
                    TABLE 83 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 84 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 85 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 86 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 87 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 88 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030–2032 (USD MILLION)
    9.3 DERMATOLOGICAL DISEASES 
           9.3.1 INCREASING R&D ACTIVITIES FOR WOUND HEALING AND REGENERATIVE MEDICINE TO DRIVE MARKET
                    TABLE 89 EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 90 EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY REGION, 2030–2032 (USD MILLION)
                    TABLE 91 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 92 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 93 EUROPE: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 94 EUROPE: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 95 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 96 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
    9.4 MUSCULOSKELETAL DISORDERS 
           9.4.1 RISING INCIDENCE OF OSTEOARTHRITIS TO SUPPORT MARKET GROWTH
                    TABLE 97 EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 98 EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2030–2032 (USD MILLION)
                    TABLE 99 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 100 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 101 EUROPE: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 102 EUROPE: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 103 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 104 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030–2032 (USD MILLION)
    9.5 CARDIOVASCULAR DISEASES 
           9.5.1 GROWING FOCUS ON TARGETED THERAPEUTIC DEVELOPMENT TO SUPPORT MARKET GROWTH
                    TABLE 105 EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 106 EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2030–2032 (USD MILLION)
                    TABLE 107 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 108 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 109 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 110 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
                    TABLE 111 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 112 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
    9.6 OTHER APPLICATIONS 
          TABLE 113 EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
          TABLE 114 EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2030–2032 (USD MILLION)
          TABLE 115 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 116 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030–2032 (USD MILLION)
          TABLE 117 EUROPE: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 118 EUROPE: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030–2032 (USD MILLION)
          TABLE 119 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 120 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030–2032 (USD MILLION)
10 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER (Page No. - 138)
     10.1 INTRODUCTION 
             TABLE 121 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
             TABLE 122 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
     10.2 HOSPITALS 
             10.2.1 GROWING COLLABORATIONS WITH PHARMA & BIOPHARMA COMPANIES TO DRIVE MARKET
                        TABLE 123 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION)
                        TABLE 124 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2030–2032 (USD MILLION)
                        TABLE 125 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 126 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030–2032 (USD MILLION)
                        TABLE 127 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 128 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030–2032 (USD MILLION)
                        TABLE 129 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 130 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030–2032 (USD MILLION)
     10.3 CLINICS AND PHYSICIAN SETTINGS 
             10.3.1 RISING ADOPTION OF LIQUID BIOPSY KITS TO SUPPORT MARKET GROWTH
                        TABLE 131 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY REGION, 2022–2029 (USD MILLION)
                        TABLE 132 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY REGION, 2030–2032 (USD MILLION)
                        TABLE 133 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 134 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030–2032 (USD MILLION)
                        TABLE 135 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 136 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030–2032 (USD MILLION)
                        TABLE 137 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 138 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030–2032 (USD MILLION)
11 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION (Page No. - 146)
     11.1 INTRODUCTION 
             TABLE 139 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
             TABLE 140 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION, 2030–2032 (USD MILLION)
     11.2 NORTH AMERICA 
             11.2.1 NORTH AMERICA: RECESSION IMPACT
                        FIGURE 37 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET SNAPSHOT
                        TABLE 141 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 142 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
                        TABLE 143 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                        TABLE 144 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                        TABLE 145 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                        TABLE 146 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                        TABLE 147 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                        TABLE 148 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                        TABLE 149 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                        TABLE 150 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.2.2 US
                        11.2.2.1 Rising R&D initiatives for development of exosomes to drive market
                                      TABLE 151 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 152 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 153 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 154 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 155 US: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 156 US: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 157 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 158 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.2.3 CANADA
                        11.2.3.1 Increasing funding initiatives for genomic-based treatments to support market growth
                                      TABLE 159 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 160 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 161 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 162 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 163 CANADA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 164 CANADA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 165 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 166 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
     11.3 EUROPE 
             11.3.1 EUROPE: RECESSION IMPACT
                        FIGURE 38 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET SNAPSHOT
                        TABLE 167 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 168 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
                        TABLE 169 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                        TABLE 170 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                        TABLE 171 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                        TABLE 172 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                        TABLE 173 EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                        TABLE 174 EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                        TABLE 175 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                        TABLE 176 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.3.2 GERMANY
                        11.3.2.1 Commercialization of pipeline candidates to propel market
                                      TABLE 177 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 178 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 179 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 180 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 181 GERMANY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 182 GERMANY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 183 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 184 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.3.3 UK
                        11.3.3.1 Rising growth in life sciences research to drive market
                                      TABLE 185 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 186 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 187 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 188 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 189 UK: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 190 UK: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 191 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 192 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.3.4 FRANCE
                        11.3.4.1 Presence of emerging players for exosome preparation to fuel market
                                      TABLE 193 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 194 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 195 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 196 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 197 FRANCE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 198 FRANCE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 199 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 200 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.3.5 ITALY
                        11.3.5.1 Rising growth in biotech sector to boost demand
                                      TABLE 201 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 202 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 203 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 204 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 205 ITALY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 206 ITALY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 207 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 208 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.3.6 SPAIN
                        11.3.6.1 Increasing initiatives for exosome research to support market growth
                                      TABLE 209 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 210 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 211 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 212 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 213 SPAIN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 214 SPAIN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 215 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 216 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.3.7 REST OF EUROPE
                        TABLE 217 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                        TABLE 218 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                        TABLE 219 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                        TABLE 220 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                        TABLE 221 REST OF EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                        TABLE 222 REST OF EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                        TABLE 223 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                        TABLE 224 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
     11.4 ASIA PACIFIC 
             11.4.1 ASIA PACIFIC: RECESSION IMPACT
                        TABLE 225 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 226 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
                        TABLE 227 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                        TABLE 228 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                        TABLE 229 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                        TABLE 230 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                        TABLE 231 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                        TABLE 232 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                        TABLE 233 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                        TABLE 234 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.4.2 JAPAN
                        11.4.2.1 Increasing healthcare expenditure to propel market
                                      TABLE 235 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 236 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 237 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 238 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 239 JAPAN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 240 JAPAN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 241 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 242 JAPAN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.4.3 CHINA
                        11.4.3.1 Rising incidence of chronic diseases to drive market
                                      TABLE 243 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 244 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 245 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 246 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 247 CHINA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 248 CHINA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 249 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 250 CHINA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.4.4 INDIA
                        11.4.4.1 Increasing pool of start-ups and rising funding investments to fuel market
                                      TABLE 251 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 252 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 253 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 254 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 255 INDIA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 256 INDIA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 257 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 258 INDIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.4.5 SOUTH KOREA
                        11.4.5.1 Rising developments by leading market players to boost demand
                                      TABLE 259 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 260 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 261 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 262 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 263 SOUTH KOREA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 264 SOUTH KOREA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 265 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 266 SOUTH KOREA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.4.6 AUSTRALIA
                        11.4.6.1 Increasing adoption of novel therapeutics to support market growth
                                      TABLE 267 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                      TABLE 268 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                                      TABLE 269 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                                      TABLE 270 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                                      TABLE 271 AUSTRALIA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                                      TABLE 272 AUSTRALIA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                                      TABLE 273 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                                      TABLE 274 AUSTRALIA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.4.7 REST OF ASIA PACIFIC
                        TABLE 275 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                        TABLE 276 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                        TABLE 277 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                        TABLE 278 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                        TABLE 279 REST OF ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                        TABLE 280 REST OF ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                        TABLE 281 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                        TABLE 282 REST OF ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
     11.5 REST OF THE WORLD 
             11.5.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET
                        TABLE 283 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
                        TABLE 284 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
                        TABLE 285 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
                        TABLE 286 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
                        TABLE 287 REST OF THE WORLD: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
                        TABLE 288 REST OF THE WORLD: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
                        TABLE 289 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
                        TABLE 290 REST OF THE WORLD: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
             11.5.2 REST OF THE WORLD: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE (Page No. - 205)
     12.1 OVERVIEW 
     12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 
             FIGURE 39 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS (2021−2024)
     12.3 REVENUE ANALYSIS 
             FIGURE 40 REVENUE ANALYSIS OF EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, 2022−2032
     12.4 MARKET SHARE ANALYSIS 
             FIGURE 41 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: MARKET SHARE ANALYSIS (2023)
             TABLE 291 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: DEGREE OF COMPETITION
     12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                        FIGURE 42 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
             12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
                        12.5.5.1 Overall company footprint
                                      TABLE 292 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: OVERALL COMPANY FOOTPRINT
                        12.5.5.2 Regional footprint
                                      TABLE 293 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: REGIONAL FOOTPRINT
                        12.5.5.3 Product & service footprint
                                      TABLE 294 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: PRODUCT & SERVICE FOOTPRINT
                        12.5.5.4 Type footprint
                                      TABLE 295 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: TYPE FOOTPRINT
                        12.5.5.5 Application footprint
                                      TABLE 296 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: APPLICATION FOOTPRINT
     12.6 COMPETITIVE EVALUATION MATRIX: START-UPS/SMES, 2023 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 STARTING BLOCKS
             12.6.3 DYNAMIC COMPANIES
             12.6.4 RESPONSIVE COMPANIES
                        FIGURE 43 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
             12.6.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2023
                        TABLE 297 EXOSOME THERAPEUTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
     12.7 COMPETITIVE SCENARIO 
             12.7.1 DEALS
                        TABLE 298 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: DEALS, JANUARY 2021−APRIL 2024
             12.7.2 OTHER DEVELOPMENTS
                        TABLE 299 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2021−APRIL 2024
13 COMPANY PROFILES (Page No. - 216)
(Business overview, Products/Solutions/Services offered, Recent developments & MnM View)*
     13.1 KEY PLAYERS 
             13.1.1 BIO-TECHNE
                        TABLE 300 BIO-TECHNE: COMPANY OVERVIEW
                        FIGURE 44 BIO-TECHNE: COMPANY SNAPSHOT (2023)
                        TABLE 301 BIO-TECHNE: PRODUCTS/SERVICES OFFERED
                        TABLE 302 BIO-TECHNE: DEALS
                        TABLE 303 BIO-TECHNE: OTHER DEVELOPMENTS
             13.1.2 NANOFCM INC.
                        TABLE 304 NANOFCM INC.: COMPANY OVERVIEW
                        TABLE 305 NANOFCM INC.: PRODUCTS/SERVICES OFFERED
             13.1.3 SYSTEM BIOSCIENCES, LLC.
                        TABLE 306 SYSTEM BIOSCIENCES, LLC.: COMPANY OVERVIEW
                        TABLE 307 SYSTEM BIOSCIENCES, LLC.: PRODUCTS/SERVICES OFFERED
             13.1.4 CAPITAL BIOSCIENCES, INC.
                        TABLE 308 CAPITAL BIOSCIENCES, INC.: COMPANY OVERVIEW
                        TABLE 309 CAPITAL BIOSCIENCES, INC.: PRODUCTS/SERVICES OFFERED
             13.1.5 AMSBIO
                        TABLE 310 AMSBIO: COMPANY OVERVIEW
                        TABLE 311 AMSBIO: PRODUCTS/SERVICES OFFERED
             13.1.6 INOVIQ
                        TABLE 312 INOVIQ: COMPANY OVERVIEW
                        FIGURE 45 INOVIQ: COMPANY SNAPSHOT (2023)
                        TABLE 313 INOVIQ: PRODUCTS/SERVICES OFFERED
                        TABLE 314 INOVIQ: DEALS
             13.1.7 DIRECT BIOLOGICS LLC
                        TABLE 315 DIRECT BIOLOGICS: COMPANY OVERVIEW
                        TABLE 316 DIRECT BIOLOGICS: PRODUCTS/SERVICES OFFERED
                        TABLE 317 DIRECT BIOLOGICS: REGULATORY APPROVALS
                        TABLE 318 DIRECT BIOLOGICS: OTHER DEVELOPMENTS
             13.1.8 REGENEUS LTD
                        TABLE 319 REGENEUS LTD: COMPANY OVERVIEW
                        TABLE 320 REGENEUS LTD: PRODUCTS/SERVICES OFFERED
             13.1.9 CUREXSYS
                        TABLE 321 CUREXSYS: COMPANY OVERVIEW
                        TABLE 322 CUREXSYS: PRODUCTS/SERVICES OFFERED
             13.1.10 AEGLE THERAPEUTICS
                        TABLE 323 AEGLE THERAPEUTICS: COMPANY OVERVIEW
                        TABLE 324 AEGLE THERAPEUTICS: PRODUCTS/SERVICES OFFERED
*Details on Business overview, Products/Solutions/Services offered, Recent developments & MnM View might not be captured in case of unlisted companies.
     13.2 OTHER PLAYERS 
             13.2.1 MERCY BIOANALYTICS
                        TABLE 325 MERCY BIOANALYTICS: COMPANY OVERVIEW
             13.2.2 NANOSOMIX, INC.
                        TABLE 326 NANOSOMIX, INC.: COMPANY OVERVIEW
             13.2.3 EXONOX BIOSCIENCES, INC.
                        TABLE 327 EXONOX BIOSCIENCES, INC.: COMPANY OVERVIEW
             13.2.4 MULTIMMUNE GMBH
                        TABLE 328 MULTIMMUNE GMBH: COMPANY OVERVIEW
             13.2.5 CAPRICOR THERAPEUTICS, INC.
                        TABLE 329 CAPRICOR THERAPEUTICS, INC.: COMPANY OVERVIEW
             13.2.6 EVOX THERAPEUTICS
                        TABLE 330 EVOX THERAPEUTICS: COMPANY OVERVIEW
             13.2.7 ILIAS BIOLOGICS INC.
                        TABLE 331 ILIAS BIOLOGICS, INC.: COMPANY OVERVIEW
             13.2.8 RION
                        TABLE 332 RION: COMPANY OVERVIEW
             13.2.9 EXOGENUS THERAPEUTICS
                        TABLE 333 EXOGENUS THERAPEUTICS: COMPANY OVERVIEW
             13.2.10 EVERZOM
                        TABLE 334 EVERZOM: COMPANY OVERVIEW
             13.2.11 KIMERA LABS
                        TABLE 335 KIMERA LABS: COMPANY OVERVIEW
14 APPENDIX (Page No. - 244)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS